Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects With Light Chain (AL) Amyloidosis

NCT04973137 is registered in ClinicalTrials.gov with Prothena Biosciences Ltd. as lead sponsor.

NCT NCT04973137
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04973137 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects With Light Chain (AL) Amyloidosis
Lead sponsor
Prothena Biosciences Ltd.
Phase
Phase 3
Overall status
Terminated
Start date
August 30, 2021
Completion date
June 20, 2025
Enrollment
208 (actual)
Sites
110

Conditions

As the registry lists them; a condition with its own page is linked.

light chain (al) amyloidosis